Annexon, Inc. (ANNX) shares are gaining more than 29 percent on Tuesday morning trade after the company announced a positive results for a phase 3 trial of C1q blocking antibody ANX005 in Guillain-Barre Syndrome. The trial met its primary endpoint with ANX005 30 mg/kg with statistically significant improvement.
Currently, ANNX is at $5.99, up 30.26 percent from the previous close of $4.58, on a volume of 36,935,980.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.